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Objective: To study anxiety as a variable of the mid- and long-term psychological impact of pre-
symptomatic testing for three autosomal dominant late-onset disorders – Huntington’s disease (HD),
Machado-Joseph disease (MJD) and familial amyloid polyneuropathy (FAP) TTR V30M – in a
Portuguese sample.
Methods: This cross-sectional study included 203 participants: 170 (83.7%) underwent pre-symptomatic
testing for FAP, 29 (14.3%) for HD, and 4 (2%) for MJD. Of the 203 participants, 73 (36.0%) were
asymptomatic carriers, 29 (14.5%) were symptomatic carriers, 9 (4.5%) were diagnosed with FAP and had
a liver transplant, and 89 (44.5%) were non-carriers. Most were women (58.1%) and married (66.5%). The
anxiety variable was assessed using the Zung Self-Rating Anxiety Scale (SAS).
Results: The anxiety scores were higher for symptomatic carriers and for those who underwent
psychological support consultations over the years. For symptomatic carriers, the mean scores were
superior to 40 points, which reflects clinical anxiety.
Conclusion: Although it was not possible to differentiate between the mid- and long-term
psychological impacts, this study supports the conclusion that the proximity to the age of symptoms
onset might be a trigger for anxiety.
Keywords: Psychology; anxiety; middle- and long-term impact; neurodegenerative diseases;
pre-symptomatic testing
Introduction
For the last two decades, a significant number of diagnostic
or presymptomatic tests (PST) and genetic counseling
protocols for late-onset neurological disorders (LOND) such
as Huntington’s disease (HD), Machado-Joseph disease
(MJD), or familial amyloid polyneuropathy (FAP) TTR V30M –
a replacement of valine by methionine at position 30 and
the mutation most commonly found in FAP – have been
developed and applied.1-5 PST can be used to assist in the
prediction of who will develop late-onset disease symptoms
in the future.1,3,6
HD, MJD, and FAP are incurable, highly debilitating,
and may exhibit a broad spectrum of symptoms.7 HD is
the most studied of these three,3,8,9 largely due to the
early discovery of its relevant genetic marker.10 A PST
protocol for subjects at risk for HD was first used in 1986
in Canada and in the U.S.,11,12 being extended to Europe
in the 1990s. Those programs have resulted, in the past
20 years, in numerous studies about the importance of
PST.7-10,13,14 Although most report on short-term results
of PST, some literature already presents long-term
psychosocial impacts of HD predictive testing.3,11,14-19
Two very specific Portuguese diseases, MJD and FAP,
also follow a severe neurodegenerative pathway and
remain until now without an effective treatment or cure.
For MJD, it is important to highlight the frequency of
cerebellar ataxia, progressive external ophthalmoplegia,
and pyramidal signs.20-22 The age at onset is variable, but
MJD rarely happens during the first decade of life and
after 70 years of age. Most people experience the first
signs between 25 and 55 years of age, with the mean age
at onset around 40 years.20 Disease duration is on
average 20 years; only 20% of the patients survive after
30 years of being diagnosed.7 In Portuguese patients, the
mean age at onset is around 40.5 years, with mean
duration of disease of 15.6 years (minimum of 7 years and
maximum of 29 years).21 It was not until 1993 that Takiyama
et al.23 located the MJD gene on chromosome 14, a finding
that was later confirmed in the Portuguese population by
Sequeiros.21
The genetic mutation present in FAP leads to the
production of an amyloid protein, which is immunologically
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related to transthyretin (TTR), that is abnormally degraded,
precipitated, and stored in body tissues as an amyloid
substance.24 It is then deposited in various organs, leading
to progressive limitation25,26 affecting peripheral nerves –
gradually expressed as digestive, cardiac, genitourinary,
dermatological disturbances – and also motor and sensory
members, producing a state of cachexia that will lead to
death25 after an average of 11 years of great suffering.27
Recent epidemiological studies report that Portuguese
patients begin to show the first symptoms at about 34 years.
However, the age range is wide, with the youngest individual
experiencing the first symptoms at only 20 years of age, and
the oldest, at 80 years.28
Presymptomatic diagnosis has been available for FAP
since 1984.25 In these last decades, there is a medical
intervention for this genetic disease that prevents its
symptomatic evolution, which is liver transplantation.
More recently, a drug, tafamidis, has been developed
for the treatment of FAP. Tafamidis acts in a similar way
to transplantation.29
Regardless of the differences between these LOND, all
involve a similar process of learning about genetic status.
Several short-term psychosocial studies with families at risk
and their descendants have been conducted in order to
investigate the psychosocial impact of PST.7,13,30-33 Those
studies have generally shown a decrease in anxiety scores
from the pre-test to the post-test evaluation.2,13 The few mid-
and long-term studies available suggest that, in general, there
is an absence of negative impact after some years,11,16,19
specifically in relation to anxiety levels. The study by
Decruyenaere et al.15 indicates a decrease in the score for
anxiety in the long run. It is thus important to study the mid
(4 years) and long-term (7 and 10 years) psychological impact
of PST in HD with inclusion of the other two neurodegenera-
tive diseases, MJD and FAP.14-16,18
In the past 17 years, the Center for Predictive and
Preventive Genetics (CGPP) at the Institute for Molecular
and Cell Biology (Instituto de Biologia Molecular e Celular,
IBMC), Universidade do Porto, has provided multidisci-
plinary support for LOND through a national reference
protocol for genetic counseling and psychosocial support
for people at risk of suffering such progressive and
debilitating disorders.1 The main objective of the present
study was to investigate the mid- and long-term con-
sequences of PST, as suggested by Timman et al.16 in
the Portuguese context, a reality that includes other
LOND beyond HD. Our hypothesis was that the levels of
anxiety would increase for carriers and decrease for non-
carriers of HD, MJD, and FAP in the mid and long-term
after disclosure of PST results and with the proximity of
the age of onset of the symptoms.
Methods
A descriptive cross-sectional study was designed based
upon data collected from medical records. Individuals who
had completed the 1 year PST protocol for HD, MJD, and
FAP at the CGPP service, who had undergone psycho-
social assessment within CGPP for at least 3 years, and
who had signed a written consent form authorizing their
data to be used for scientific purposes, were included.
The study protocol was approved by the IBMC Ethics
Committee. Participants (carriers and non-carriers of HD,
MJD, and FAP) were contacted only once to answer a
sociodemographic and clinical status questionnaire and
the Zung Self-Rating Anxiety Scale (SAS).34
A primary assessment to study the short-term con-
sequences of PST, with a subsequent update to investi-
gate the mid- and long-term consequences of PST in the
present study, was conducted with the 686 participants
who had completed their PST protocol at least 3 years
earlier. After the primary assessment, a set of specific
questionnaires was mailed to these individuals. Out of the
initial 686 participants, 203 answered the questionnaires
and comprised the present study sample.
Sociodemographic variables (gender, age, profession,
and marital status) and a clinical variable (current clinical
status) were collected using a questionnaire. As in previous
Portuguese studies,2,13 the variable anxiety was assessed
using the Portuguese version35 of the SAS.34 This scale
measures anxiety clinical symptomatology through 20 items
rated on a 4-point Likert scale, ranging from 1 – rarely or
never to 4 – most or all of the time.
The construct was evaluated based on the description of
the most common signs and symptoms of anxiety in terms
of four dimensions (or subscales): cognitive (items 1, 2, 3, 4,
and 5) for a maximum of 20 points; motor (items 6, 7, 8,
and 9) for a maximum of 16 points; vegetative (items 10, 11,
12, 13, 14, 15, 16, 17, and 18) for a maximum of 36 points;
and central nervous system (CNS) (items 19 and 20) for a
maximum of 8 points. The score ranges between 20 and 80
and the cutoff point is 40.35
Procedures
The study was conducted with a group of participants who
signed a written informed consent form, completed the
1-year PST protocol for genetic counseling for HD, MJD,
and FAP, and underwent psychosocial assessment within
CGPP for more than 3 years before answering the
questionnaire, regardless of diagnostic status (carriers
or non-carriers). Subsequently, a set of specific ques-
tionnaires was sent by mail depending on whether the
subject was a carrier or a non-carrier. The addition of
some items allowed the update of the sociodemographic
information (marital status, profession, and significant life
changes). Some questions about the current clinical
status were also included in the questionnaire, i.e., in
the specific case of carriers, if the person remained
asymptomatic or had developed symptoms. Also, some
questions concerning the existence of any environment
connection (family context, for example) of the respective
disease were also added. SAS was sent along with the
sociodemographic questionnaires. A cover letter contain-
ing information about the investigation to be conducted,
namely, identification of researchers and the nature and
aims of the study was also included. That same letter also
underscored the principle of confidentiality displayed
when these participants originally registered on the PST
protocol. A 6-month time frame was considered to receive
the responses by mail. The answers received were
entered into a database.
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Data analysis
Statistical analysis was performed using SPSS version
19.0.36 Descriptive (mean, standard deviation, minimum
value and maximum value) and inferential (analysis of
variance [ANOVA] and correlations) analyses were used.
Results
Description of the sample
In terms of the main sociodemographic features, 58.1% of
the 203 participants were female, and 43.3% were aged up
to 30 years. Most of the participants who had been single at
the time of the completion of the 1-year PST protocol were
married when the questionnaire was applied. Regarding
professions, most participants had professions involving a
high level of responsibility (1st Graffar Index; by the
Classification of Graffar, the 1st group includes leadership,
direction, and high responsibilities), and had completed higher
education. Retirees made up the second largest group of
participants. Most participants, 83.7%, underwent the PST
for FAP, and 36.5% of 203 were carriers. Of participants
diagnosed as carriers, 14.5% had become symptomatic. Of
individuals with FAP, 4.5% had already accomplished liver
transplantation (Table 1).
At the time of the study, 32.2% of participants had known
their genetic status for at least 4 years, 47% for at least
7 years, and 20.8% for at least 10 years, as presented in
Table 2.
As compared to the data described in Table 1, Table 2
shows an increase in the mean age of participants for the
group having completed PST 7 years earlier (31-40 years).
In terms of the profession, the number of retired participants
also increased.
SAS items descriptive analysis for the total sample
and gender variables
Descriptive analysis was applied to the 20 items of the
SAS, and included mean, standard deviation, and percen-
tage of symptomatic responses, i.e., responses scored
with 2, 3, or 4 points according to the Likert scale, for the
total sample and gender subsamples. Globally, women
presented significantly higher means in some of the items
that related to anxiety symptoms, such as dizzy spells,
restlessness, headaches, neck and back pain, and
breathing difficulty. Item 5, which is ‘‘I feel that everything
is all right and nothing bad will happen,’’ presented the
higher percentage of symptomatic responses.
Total SAS and subscales for the total sample and
gender subsamples
Mean and standard deviation of the total and all SAS
subscales for the total sample and gender subsamples
were calculated (Table 3), considering the three times
elapsed since diagnosis, i.e., 4, 7 and 10 years (Table 4).
Analyzing Table 3, women had overall higher means than
men, concerning the total SAS and all SAS subscales.
Regarding the total SAS, 16.8% of the participants
presented total scores superior to 40 points, which
reflects pathological anxiety (M = 44.81; SD = 4.19). This
specific group of anxious individuals belongs essentially
to the group of participants who completed the PST
7 years before answering the questionnaire (53.1%), and it
is mostly composed of females (78.5%), married persons
(68.8%), and carriers (65.6%), already with symptoms,
mostly with FAP (87.5%). Also, these individuals were the
ones who received psychological evaluation and support
through the years after the test results.
Concerning the three times since diagnosis – 4, 7, and
10 years – the mean and standard deviation values were
Table 1 General description of the sample
Participants
(n=203)
Gender
Female 118 (58.1)
Male 85 (41.9)
Age (years)
p 30 88 (43.3)
31-40 62 (30.5)
41-50 20 (9.9)
51-60 22 (10.8)
61-70 8 (3.9)
X 71 3 (1.5)
Marital status (at time of genetictesting)
Single 104 (51.2)
Married 89 (43.8)
Divorced 5 (2.5)
Widow 2 (1.0)
Marital status (current)
Single 53 (26.6)
Married 132 (66.5)
Divorced 10 (5.0)
Widow 3 (1.5)
Profession
Retired 40 (19.7)
Unemployed 19 (9.4)
Student 15 (7.4)
1st Graffar index 59 (29.1)
2nd Graffar index 11 (5.4)
3rd Graffar index 4 (2.0)
4th Graffar index 22 (10.8)
5th Graffar index 33 (16.3)
Disease
HD 29 (14.3)
MJD 4 (2.0)
FAP 170 (83.7)
Test result
Carrier 112 (55.2)
Non-carrier 91 (44.8)
Clinical status (current)
Non-carrier 89 (44.5)
Asymptomatic carrier 73 (36.5)
Symptomatic carrier 29 (14.5)
Liver transplanted (FAP carriers) 9 (4.5)
FAP = familial amyloid polyneuropathy; HD = Huntington’s disease;
MJD = Machado-Joseph disease.
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very similar for the total scores and all subscales, as
observed in Table 4.
Comparison of total SAS and subscales mean for
different variables
In this section, only statistically significant results will be
presented.
The gender variable showed that women presented higher
means than men for the total SAS and for the vegetative and
CNS subscales, with statistically significant values. Regard-
ing the sociodemographic variable age, significant results
were found merely on the motor subscale (F = 2.47; df = 5;
p = 0.034): participants aged between 41 to 50 years and 61
to 70 years presented the highest means for motor anxiety
(Mp30 = 6.30; M31-40 = 6.77; M41-50 = 7.83; M51-60 = 6.14;
M61-70 = 8.00; MX71 = 6.33). Another sociodemographic
variable that presented significant results was profession.
This variable exhibited statistically significant values for the
total SAS and all SAS subscales: participants with the 2nd
Table 2 Distribution of participants according to time since diagnosis (4, 7 and 10 years)
Number of years since PST protocol 4 years 7 years 10 years F df p-value
Gender
Female 33 (58.1) 58 (61.1) 26 (61.9) 1.568 1 0.212
Male 32 (41.9) 37 (38.9) 16 (38.1)
Age (years)
p 30 32 (49.2) 40 (42.1) 15 (35.7)
31-40 14 (21.5) 32 (33.7) 16 (38.1)
41-50 7 (10.8) 10 (10.5) 3 (7.1) 0.847 5 0.518
51-60 9 (13.8) 6 (6.3) 7 (16.7)
61-70 2 (3.1) 5 (5.3) 1 (2.4)
X 71 1 (1.5) 2 (2.1) 0 (0.0)
Marital status (current)
Single 31 (26.6) 21 (22.6) 8 (20.0)
Married 30 (66.5) 65 (69.9) 30 (75.0) 2.066 3 0.087
Divorced 1 (5.0) 5 (5.4) 1 (2.5)
Widow 0 (0.0) 2 (2.1) 1 (2.5)
Profession
Retired 15 (23.1) 15 (15.8) 10 (23.8)
Unemployed 7 (10.8) 8 (8.4) 4 (9.5)
Student 4 (6.2) 9 (9.5) 2 (4.8)
1st Graffar index 19 (29.2) 29 (30.5) 11 (26.2) 0.466 7 0.858
2nd Graffar index 2 (6.2) 6 (6.3) 1 (2.4)
3rd Graffar index 3 (4.6) 0 (0.0) 1 (2.4)
4th Graffar index 6 (9.2) 11 (11.6) 5 (11.9)
5th Graffar index 7 (10.8) 17 (17.9) 8 (19.0)
Disease
HD 15 (23.1) 11 (11.6) 3 (7.1)
MJD 4 (6.2) 0 (0.0) 0 (0.0) 6.756 2 0.001
FAP 46 (70.8) 84 (88.4) 39 (92.9)
Test result
Carrier 35 (53.8) 52 (54.7) 25 (59.5) 0.291 1 0.590
Non-carrier 30 (46.2) 43 (45.3) 17 (40.5)
Clinical status (current)
Non-carrier 30 (46.2) 41 (44.1) 17 (41.5)
Asymptomatic carrier 25 (38.5) 33 (35.5) 15 (36.6)
Symptomatic carrier 9 (13.8) 15 (16.1) 5 (12.2) 1.251 3 0.292
Liver transplanted (FAP carriers) 1 (1.5) 4 (4.30) 4 (9.8)
Data presented as n (%). Significant results are in bold.
df = degrees of freedom; F = Snedcor’s distribution; FAP = familial amyloid polyneuropathy; HD = Huntington’s disease; MJD =Machado-Joseph disease.
Table 3 Results of the total SAS and SAS subscales for the total sample and gender variables
SAS
Total sample Female Male
Mean 6 SD n Mean 6 SD n Mean 6 SD n
Total SAS 31.9167.59 191 33.2468.01 114 29.9566.49 77
Cognitive subscale 7.8362.32 192 8.0962.38 114 7.4562.18 78
Motor subscale 6.6362.15 195 6.8662.29 115 6.3061.89 80
Vegetative subscale 14.0263.33 196 14.7563.51 115 12.9962.75 81
CNS subscale 3.5261.37 196 3.7061.42 115 3.2761.27 81
CNS = central nervous system; SAS = Zung Self-Rating Anxiety Scale; SD = standard deviation.
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Graffar Index, retired, and unemployed participants always
presented the highest mean values.
In relation to clinical status, significant results were found
for the variable test result with carriers systematically
presenting higher means for total SAS, as well as for the
motor and vegetative subscales, when compared to non-
carriers (Table 5).
When analyzing why carriers presented the highest
means in the total SAS and in the motor and vegetative
subscales (Table 5), it became clear that participants with
higher means were symptomatic, followed by liver
transplanted FAP patients, as shown in Table 6.
Considering the symptomatology of carriers regarding
the answer to the specific question ‘‘still without symp-
toms?,’’ significant values were found for all subscales
and the total SAS score. It must be highlighted that
participants who were still free of symptoms presented
lower mean values than those who considered to already
have symptoms. On the contrary, the participants that
answered ‘‘perhaps’’ were the ones presenting the high-
est means.
Significant differences were found in what concerns the
symptomatology mentioned by carriers who answered ‘‘no’’
and ‘‘perhaps’’ to the question ‘‘still without symptoms,’’ in
the scores of the total SAS and three of its subscales –
motor, vegetative and CNS. Accordingly, participants who
reported severe and moderate symptoms presented higher
mean values than those reporting other symptomatology, or
than those participants who did not specify their symptoms
in the questionnaire.
Significant differences were also found for the answer to
the question ‘‘Have you ever had psychological evaluation
and support?’’ Those differences were identified for the total
SAS score and for three of its subscales (motor, vegetative
and CNS). It can be stated that participants who had
accomplished psychological evaluation presented higher
mean values than those who had only been submitted to
one psychological evaluation and support, and also than
those who had never received psychological evaluation and
support. This latter group of participants presented the
lowest means.
Regarding the existence of a meaningful life change,
significant results were found concerning the total SAS
score and the cognitive and vegetative subscales values.
Carriers who experienced meaningful life changes showed
higher means than other carriers that did not mentioned any
type of life changes.
Finally, and regarding non-carriers, significant differ-
ences were found for the answer to the question ‘‘Issues
about the PST disease that bother you?,’’ in terms of the
total SAS score and the vegetative and CNS subscales
values. Non-carriers who had no problems talking about
the PST disease issues presented lower mean values
than those participants for whom PST still represented a
serious discomfort.
Statistical analyses were also carried out taking into
account the three times since diagnosis (4, 7 and 10 years),
but no statistically significant differences were found between
them.
Table 4 Results of the total SAS and SAS subscales according to time since diagnosis (4, 7 and 10 years)
Number of years since PST
4 years 7 years 10 years
Mean 6 SD n Mean 6 SD n Mean 6 SD n
Total SAS 31.0267.99 63 32.6367.65 88 31.8566.87 39
Cognitive subscale 7.7062.57 64 7.8962.31 88 7.9061.94 39
Motor subscale 6.3362.35 64 6.8462.18 90 6.6561.69 40
Vegetative subscale 13.8663.50 65 14.1963.28 90 13.9563.26 40
CNS subscale 3.3461.27 65 3.7161.45 90 3.4361.36 40
CNS = central nervous system; SAS = Zung Self-Rating Anxiety Scale; SD = standard deviation.
Table 5 Comparison between mean values for the total SAS
and two SAS subscales (motor and vegetative) according to
diagnostic status
Diagnostic status Mean F df p-value
Total SAS
Carrier 33.07
Non-carrier 30.50 5.53 1 0.020
Motor subscale
Carrier 6.93
Non-carrier 6.26 4.85 1 0.029
Vegetative subscale
Carrier 14.67
Non-carrier 13.23 14.17 1 0.002
df = degrees of freedom; F = Snedcor’s distribution; SAS = Zung
Self-Rating Anxiety Scale.
Table 6 Comparison between mean values of the total SAS
and two SAS subscales (motor and vegetative) according to
clinical status
Clinical status Mean F df p-value
Total SAS
Non-carrier 30.54
Asymptomatic carrier 31.28
Symptomatic carrier 37.12
Liver transplanted (FAP carriers) 34.86 5.95 3 0.001
Motor subscale
Non-carrier 6.28
Asymptomatic carrier 7.71
Symptomatic carrier 8.85
Liver transplanted (FAP carriers) 8.71 8.45 3 0.000
Vegetative subscale
Non-carrier 13.23
Asymptomatic carrier 13.78
Symptomatic carrier 16.64
Liver transplanted (FAP carriers) 15.43 8.92 3 0.000
df = degrees of freedom; F = Snedcor’s distribution; SAS = Zung
Self-Rating Anxiety Scale.
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Discussion
In the present study, the results obtained show that the
number of carriers was larger than that of non-carriers,
supporting the trend revealed in previous studies in which
the number of carriers increased and the number of
non-carriers decreased over the follow-up protocol.13,31
As shown in the statistical descriptive analysis, and as
previous studies have suggested,2,13,18,37 the female
population presented higher values of psychopathology,
i.e., higher levels of anxiety symptoms. Analyzing each
item of the SAS, women present higher mean values than
men in all SAS items. The items that included implicit
references to restlessness and concerns about the future
received the highest scores for both female and male
gender.
Similarly to other investigations focusing on the short-
term psychological impact of PST,2, 3, 7,13,30-32,37,38 the
mid- and long-term mean SAS values in this study were,
in general, lower than the SAS cutoff point indicating
clinical anxiety (40 points), apparently suggesting the
absence of a negative psychological impact resulting from
the PST long-term outcome, as supported by Timman
et al.16 Surprisingly, the mean values obtained indicate a
similar trend even for the group of participants who
underwent PST longer than 7 or 10 years prior to this
study, suggesting that the increased probability of onset
of symptoms did not influence the psycho-affective
condition of participants. However, the group with total
SAS scores higher than 40 points represented 16.8% of
the total sample, and most had completed the PST
7 years earlier, clearly indicating the relevance of the
elapsed time and the proximity of the age for onset of
symptoms.
The apparently low total SAS scores might be justified
by the existence of a self-selection, prior to PST, of those
participants who became psychologically better prepared
in the past2,3,7 and incidentally the same ones who
participated in the present study.16 The apparently lower
psychological impact in the mid- and long-term might be
due to the fact that people who were less psychologically
disturbed since the beginning, prior to the PST, were the
ones who did not drop out of the follow-up and did not
avoid facing the reality of the disease.
Participants with ages between 61 to 70 years old
presented higher motor anxiety followed by those with
age ranging from 41 to 50 years old. The latter results can
be easily interpreted as reflecting the approach of the age
of onset of symptoms. For the former, the reason is
related to the age level.
Regarding the professions, in the case of participants
who were retired or unemployed, or in the case of
participants with medium levels of responsibility (Graffar 2
index), it can be concluded that they presented higher
scores for the total SAS and all the SAS subscales. The
fact of being unemployed and the possibility of economic
problems or, conversely, having a stressful job, which
inevitably involves increased responsibility, might explain
these results. It is not possible to exclude the possibility
that these individuals were already presenting symptoms
that compromised their job security. In relation to the
clinical variables, carriers presented the highest mean in
the total SAS score and in the motor and vegetative
subscales. These two subscales are focused on bodily
sensations, which might be related with possible symp-
toms of disorder.
Analyzing in more detail the current clinical status of the
carriers, the participants who were already symptomatic,
followed, in the case of FAP, by liver transplanted patients,
presented higher levels in the total SAS scores and in the
motor and vegetative subscales. This suggests that the
self-experience of each subject with the specific symptoms
of the disorder determines the level of anxiety. Only when
experiencing real symptoms do individuals seem to
focalize on their physical sensations and exteriorize their
internal discomfort. This becomes clear when the question
‘‘Still without symptoms?’’ was asked to carriers. Indivi-
duals answering ‘‘no’’ or ‘‘perhaps’’ had the highest scores
in the total SAS scores and in the motor and vegetative
subscales. They had the perspective or the certainty of
already having the symptoms, and that fact increased their
anxiety. As the severity of the symptoms increased, so did
the anxiety scores associated with them. Participants who
indicated to have mild to severe symptoms were those with
the highest scores in the total SAS and in all SAS
subscales, with the total scores reaching a value that
indicates clinical anxiety, above 40 points.
Carriers who underwent several psychological evalua-
tion and support consultations presented the highest
mean in the total SAS and in all SAS subscales. These
results seem to corroborate the idea that the individuals
who realize, and accept, to present some emotional
anxious disturbance, were the ones who requested this
kind of assistance.
Because we were aware that anxiety results could have
been related to variables other than PST outcomes, carriers
were questioned about the existence of a meaningful life
change since their participation in the PST protocol. Parti-
cipants reporting significant changes in their lives were the
ones who presented the highest values in the total SAS
and in the motor and vegetative subscales. Although no
statistically significant results were found regarding the type
of life change (and therefore these results have not been
reported), one changes mentioned was ‘‘loss or illness of a
close relative.’’ This leads to the hypothesis that living closely
with the anguishing reality of the disorder and the consequent
changes in day-to-day life may account for higher values of
anxiety.
Regarding non-carriers, significant results were obtained
for the answer to ‘‘Issues about the PST disease that
bother you?’’ Those individuals who considered having no
problem talking about the disease presented the lowest
mean value for anxiety.
Taking into account the times elapsed since PST, of 4,
7, and 10 years, it is possible to state that no signifi-
cant results were obtained. Accordingly, and taking into
consideration the anxiety levels, it is not possible to affirm
that there might be significant differences between the
psychological impact in the mid- and long-term. The
proximity to the age of symptoms onset might be a factor
that triggers the level of psychological disturbance of
individuals. It is important to highlight that from the group
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of participants in this study, the most anxious ones had
undertaken the PST 7 years earlier.
This study does not corroborate previous studies which
have suggested an absence of negative long-term psycho-
logical impact resulting from the PST,16 namely anxiety
levels, suggested to decrease over time.15 Considering that
the total SAS and subscales mean values herein obtained
were higher than those referred in a previous study des-
cribing short-term psychological impact,13 it might be con-
sidered that the anxiety level increases over time.
Unlike Decruyenaere et al.,15 we included actual carriers,
who already presented symptoms. As in the study by
Licklederer et al.,39 which investigated the long-term mental
health in subjects who underwent PST, psychological distur-
bance was detected in the group of symptomatic carriers,
with no significant differences between asymptomatic carriers
and non-carriers. In fact, only when participants began to
experience symptoms with some degree of severity did the
total SAS mean surpass the cutoff point of 40 points,
revealing the presence of clinical anxiety.
Although this study reveals important data about the
knowledge of the reality of the PST in the mid- and long-term,
some limitations must be addressed. The main constraint
refers to the differences of frequencies between the three
diseases. The decision to include HD and MJD cases had to
do with one of the aims of the study, which was to assess all
the subjects undergoing PST. However, this may have not
been the best decision, since it prevents the comparison
between the diseases. This study is not a longitudinal study,
which may have influenced the results, since it is difficult to
have a perspective of continuity over the years, and it is
focused on the same subjects. A future multivariate approach
would help to prevent concurrent effects of variables such as
gender, age, or profession. Another constraint is related to
the type of contact selected to obtain the answers to the
questionnaire, in order to gather data. The contact was made
by mail. Although the planned strategy of contact was
efficient to increase the number of participants, it also meant
a limited control regarding the conditions under which the
participants answered the questionnaire. In order to better
understand some of the results, it would have been useful to
include additional family variables such as whether the
participants had children. Finally, it can be said that the times
since PST taken into consideration in the present study were
different from those analyzed in previous studies, which
makes comparisons between results more difficult. This may
have prevented some degree of understanding, relating the
fact that the level of psychological impact on subjects may
also depend on a larger or smaller duration of the period of
time due to the completion of PST.
In conclusion, the levels of anxiety seem to decrease
in asymptomatic carriers (despite the proximity of the
age of onset of the symptoms) and non-carriers, only
increasing for carriers who already have symptoms. This
happens for the three diseases studied. It is relevant to
highlight the importance of psychological counseling
already included in the CGPP protocol and its role in
reducing anxiety levels or possibly even in preventing its
manifestation.
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